Data from epgonline.org - Curated by EPG Health - Date added 26 April 2019
The 1st ESMO Breast Cancer annual congress took place from 2-4 May 2019 in Berlin, Germany with the aim of bringing together breast cancer researchers and clinicians who have a specific interest in innovation and care. Several reports were issued during the congress, including:
- Global HER2 testing survey raises questions about priorities for breast cancer resources: A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer, especially in poorer countries.
- Integrated care ahead of innovation in breast cancer: A report by Prof Giuseppe Curigliano suggesting that therapeutic innovations should go hand in hand with a multidisciplinary, fully integrated approach to patient care.
- Breast cancer in young women: good-outcomes with advised therapy: Breast cancer in young women is often characterised by more aggressive biological features as compared to those arising in older patients - but outcomes are good when guideline-recommended treatments are given, according to ESMO Spokesperson Dr. Matteo Lambertini
See our CDK4/6 Inhibitors in Metastatic Breast Cancer Learning Zone that details clinical education, the CDK 4/6 pathway and treatments including palbociclib, ribociclib and abemaciclib.